Arbutus Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Arbutus Biopharma has a total shareholder equity of $106.9M and total debt of $5.3M, which brings its debt-to-equity ratio to 5%. Its total assets and total liabilities are $140.4M and $33.6M respectively.
Key information
5.0%
Debt to equity ratio
US$5.32m
Debt
| Interest coverage ratio | n/a |
| Cash | US$127.79m |
| Equity | US$106.89m |
| Total liabilities | US$33.55m |
| Total assets | US$140.44m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I9DN's short term assets ($132.8M) exceed its short term liabilities ($18.9M).
Long Term Liabilities: I9DN's short term assets ($132.8M) exceed its long term liabilities ($14.6M).
Debt to Equity History and Analysis
Debt Level: I9DN has more cash than its total debt.
Reducing Debt: I9DN's debt to equity ratio has reduced from 22.3% to 5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I9DN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: I9DN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 2.3% each year.